<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602159</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00027939</org_study_id>
    <nct_id>NCT01602159</nct_id>
  </id_info>
  <brief_title>Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)</brief_title>
  <acronym>ROBUST</acronym>
  <official_title>Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled trial to compare clinical improvement, cost&#xD;
      effectiveness and patency rates between new and improved Nitinol stents and open bypass&#xD;
      surgery in the superficial femoral artery disease.&#xD;
&#xD;
      Secondary outcomes also include comparing quality of life, re-intervention rate, mortality,&#xD;
      morbidity and time to return to work or regular activities.&#xD;
&#xD;
      Patients with superficial femoral artery lesions will be considered. Patients with TASC II A&#xD;
      lesions will not be randomized but treated with PTA/stenting as standard of care. Patients&#xD;
      with TASC II B and C lesions will be prospectively randomized into either receiving open&#xD;
      bypass or stenting.&#xD;
&#xD;
      Patients with TASC D lesions will be treated with open bypass surgery after angiography.&#xD;
&#xD;
      The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on&#xD;
      all enrolled the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>12 Month Post Operatively</time_frame>
    <description>Clinical Improvement is measured as at least 1 Rutherford category</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency rate</measure>
    <time_frame>12 Month Post Operatively</time_frame>
    <description>Primary, primary assisted and secondary at 6, 12 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>12 Month Post Operatively</time_frame>
    <description>Cost Effectiveness factoring procedure and hospital admission costs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement</measure>
    <time_frame>12 Month Post Operatively</time_frame>
    <description>Improvement of quality of life measured using VQL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention rate</measure>
    <time_frame>12 Month Post Operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success of both treatment modalities</measure>
    <time_frame>12 Month Post Operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day operative mortality</measure>
    <time_frame>12 Month Post Operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to work and regular activities</measure>
    <time_frame>12 Month Post Operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity associated with both treatment modalities</measure>
    <time_frame>12 Month Post Operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Superficial Femoral Artery Stenosis</condition>
  <condition>Superficial Femoral Artery Occlusion</condition>
  <condition>Claudication</condition>
  <condition>Rest Pain</condition>
  <arm_group>
    <arm_group_label>Open Bypass Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open Bypass Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angioplasty and Stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Bypass Surgery</intervention_name>
    <description>Open Bypass Surgery with Autogenous vein or PTFE Graft</description>
    <arm_group_label>Open Bypass Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angioplasty and Stenting</intervention_name>
    <description>Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).</description>
    <arm_group_label>Angioplasty and Stenting</arm_group_label>
    <other_name>Life Stent flexStar Stent System by Bard Inc. Tempe AZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical Inclusion:&#xD;
&#xD;
          1. Must be at least 18 years of age.&#xD;
&#xD;
          2. Patient has been informed of the nature of the study, and has provided written&#xD;
             informed consent, approved by the appropriate Institutional Review Board (IRB)/Medical&#xD;
             Ethics Committee (MEC) of the respective clinical site.&#xD;
&#xD;
          3. Symptomatic patient as evidence by IC or CLI.&#xD;
&#xD;
          4. Patient has failed maximized medical treatment and exercise program.&#xD;
&#xD;
          5. Patient has a resting ABI &lt; 0.9 or an abnormal exercise ABI if resting ABI is&#xD;
             normal.Patient with non-compressible arteries (ABI &gt; 1.2) must have a TBI &lt; 0.8.&#xD;
&#xD;
          6. Patient has a de novo or restenotic lesion(s) with &gt; 50% stenosis documented&#xD;
             angiographically.&#xD;
&#xD;
          7. Patient agrees to return for all required clinical contacts following study&#xD;
             enrollment.&#xD;
&#xD;
          8. Patient has no childbearing potential or has a negative pregnancy test within one week&#xD;
             prior to the study procedure.&#xD;
&#xD;
        Anatomical Inclusion:&#xD;
&#xD;
          1. Patient with any SFA lesion&#xD;
&#xD;
          2. At least one tibial vessel runoff with &lt; 50% stenosis&#xD;
&#xD;
          3. Lesion starts start at least 1 cm distal to the deep femoral artery&#xD;
&#xD;
          4. Lesion end at least 3 cm above the knee joint&#xD;
&#xD;
          5. Target vessel reference diameter is &gt; 3 mm &amp; &lt; 6.5 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical exclusion:&#xD;
&#xD;
          1. Known allergic reaction to anesthesia not able to overcome by medication.&#xD;
&#xD;
          2. Known allergic reaction to contrast not able to overcome by medication.&#xD;
&#xD;
          3. Known history of intolerance to study medicating including ASA, clopidogrel, or&#xD;
             ticlopidine.&#xD;
&#xD;
          4. Bleeding disorder or refuses blood transfusion.&#xD;
&#xD;
          5. Prior stenting or bypass of SFA (prior PTA is not an exclusion criteria)&#xD;
&#xD;
          6. Unstable angina, recent MI within a month&#xD;
&#xD;
          7. Malignancy or other condition limiting life expectancy to &lt; 5 years.&#xD;
&#xD;
          8. Renal insufficiency (serum Cr &gt; 2.0)&#xD;
&#xD;
          9. Patient has any condition that precludes proper angiographic assessment or makes&#xD;
             percutaneous arterial access unsafe (e.g., morbid obesity).&#xD;
&#xD;
        Anatomic Exclusion:&#xD;
&#xD;
          1. Lesion &lt; 1 cm from origin of DFA&#xD;
&#xD;
          2. Lesion &lt; 3 cm from the knee joint&#xD;
&#xD;
          3. Chronic total occlusion of SFA &gt; 20cm.&#xD;
&#xD;
          4. Chronic total occlusion of CFA.&#xD;
&#xD;
          5. Proximal trifurcation occlusions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud B Malas, M.D., MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Claudication</keyword>
  <keyword>SFA</keyword>
  <keyword>Open Bypass</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

